Submitted by:
Amy Deipolyi, MD, PhD, Assistant Professor of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center
Gary A. Ulaner, MD, PhD, Associate Professor of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center

Organization:
Society of Interventional Oncology
2025 M St NW #800, Washington, DC 20036
Phone: (202) 367-1164
Email: TGreene@sio-central.org

July 30, 2020
NCCN Guidelines Panel: Breast Cancer

On behalf of the Society of Interventional Oncology, we respectfully request the NCCN Breast Cancer Guideline panel to review the enclosed data for inclusion of locoregional therapies and metabolic imaging for metastatic breast cancer.

We suggest recommending PET/CT to monitor disease progression rather than specifying it as optional and including embolotherapies for treatment of refractory hepatic metastasis.

Clinical scenario 1: Detection and monitoring metastatic disease.

The current NCCN guidelines specify that FDG PET/CT is not routinely indicated, but optional, and is “most useful in situations where standard imaging results are equivocal or suspicious.” However, studies have demonstrated that FDG PET/CT can detect unsuspected metastasis, is superior to conventional CT imaging in detecting relapse, better reflects response to treatments, and better predicts survival outcomes. We recommend that FDG PET/CT be included in the routine detection of metastatic disease and monitoring at regular intervals, rather than as an optional/trouble-shooting imaging strategy.

The following articles are relevant to this proposed change:
Clinical scenario 2: Treatment of liver-dominant hepatic metastasis refractory to systemic therapy.

Liver metastasis is associated with poorer oncologic outcomes. Liver tumors may cause abdominal pain or result in compression of the portal vein or obstruction of bile ducts. In selected patients who are not eligible for resection or ablation, transarterial therapies such as chemoembolization and radioembolization have demonstrated radiologic responses that translate to prolonged patient survival. Combining liver-directed treatments in the management of metastatic breast cancer with liver-only or liver-dominant disease can provide longer disease control while delaying the need to change to another line of systemic therapy. Also, in patients with hormonally responsive breast cancer and new-onset liver metastases, transarterial locoregional therapy can delay the initiation of systemic chemotherapy and benefit the patient’s quality of life. Studies suggest that radioembolization is superior to chemoembolization in regard to imaging response and adverse event rates. We propose including locoregional embolotherapy with radioembolization as a treatment for refractory hepatic metastasis.

The following articles are relevant to this proposed change:


We would like to thank the NCCN panel members for their time and effort in reviewing this submission.

Sincerely,

Amy Deipolyi, MD, PhD
Gary A. Ulaner, MD, PhD